WO2023067522 - PHARMACEUTICAL COMPOSITIONS
National phase entry:
Publication Number
WO/2023/067522
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060061
International Filing Date
19.10.2022
Title **
[English]
PHARMACEUTICAL COMPOSITIONS
[French]
COMPOSITIONS PHARMACEUTIQUES
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
BHASIN, Saket
Novartis Healthcare Pvt Limited, Building No. 1800 & 2700, Takshila Tech Parks & Incubation (India) Pvt. Limited.
Plot No.4, Survey No. 101, Genome Valley
Shamirpet, Hyderabad 500078, IN
KULKARNI, Swati
Novartis Healthcare Pvt Limited, Building No. 1800 & 2700, Takshila Tech Parks & Incubation (India) Pvt. Limited.
Plot No.4, Survey No. 101, Genome Valley
Shamirpet, Hyderabad 500078, IN
Priority Data
202111047878
21.10.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1753 | |
| EPO | Filing, Examination | 11507 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 7310 |
Total: 21736 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
-spiro[imidazo[1,2- ]pyridine-2,5'-isoquinoline], or a pharmaceutically acceptable salt thereof, or a free form thereof are described. Further, processes for preparing said pharmaceutical 5 compositions for oral administration and uses of said pharmaceutical compositions in the manufacture of a medicament are described.[French]
-spiro [imidazo [1,2-]pyridine-2,5'-isoquinoline], ou un sel pharmaceutiquement acceptable de celui-ci, ou une forme libre de celui-ci. En outre, l'invention concerne des procédés de préparation desdites compositions pharmaceutiques pour une administration orale et des utilisations desdites compositions pharmaceutiques dans la fabrication d'un médicament.